Investor Relations

Stock price graph
DDXS [OT] : $0.52  + 0.03
Last Updated: 3:28 PM ET on Oct 29, 2014

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

The PLAC Test for Lp-PLA2, diaDexus' flagship product, addresses key unmet medical need, providing actionable information. The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

PLAC Test Fact Sheet - January 2014 PDF

Lp-PLA2 Fact Sheet - January 2014 PDF

Heart Failure Fact Sheet - March 2014 PDF

View all »   RSSRecent Releases

Oct 29, 2014
diaDexus, Inc. to Report Third Quarter 2014 Financial Results on November 5, 2014

Sep 22, 2014
diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical Officer

View all »Events & Presentations

Nov 5, 2014 at 1:30 PM PT
3Q-2014 Conference Call


©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.